Sato Ryosuke, Matsumoto Kazuyuki, Uka Mayu, Takagi Kosei, Nishida Kenji, Tanaka Takehiro, Fujii Yuki, Tsutsumi Koichiro, Horiguchi Shigeru, Otsuka Motoyuki
Department of Gastroenterology and Hepatology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, Okayama, 700-8558, Japan.
Department of Radiology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, Okayama, 700-8558, Japan.
Clin J Gastroenterol. 2025 Apr;18(2):376-382. doi: 10.1007/s12328-025-02098-y. Epub 2025 Feb 5.
We herein report a case of pancreatic ductal adenocarcinoma (PDAC) that developed within the pancreatic duct and was initially diagnosed as an intraductal tubulopapillary neoplasm (ITPN). A 76-year-old man presented with weight loss and main pancreatic duct dilation. The imaging studies revealed a 30-mm hypovascular tumor within the main duct of the pancreatic head. An endoscopic examination with a biopsy revealed high-grade atypical epithelial cells with immunostaining patterns suggestive of ITPN. Following robot-assisted pancreaticoduodenectomy, postoperative pathology revealed conflicting features: nodular/cribriform infiltrations typical of ITPN and non-lobular replacement with scattered infiltrations characteristic of PDAC. A comprehensive genomic profiling test detected KRAS and TP53 mutations, leading to the final diagnosis of PDAC (fT3N1aM0, stage IIB). The patient received adjuvant S-1 chemotherapy and remained recurrence-free for 15 months post-surgery. This case highlights the diagnostic challenges of differentiating intraductal pancreatic tumors and demonstrates the utility of integrating genetic testing with conventional diagnostic modalities for an accurate diagnosis and appropriate treatment selection.
我们在此报告一例发生于胰管内的胰腺导管腺癌(PDAC),该病例最初被诊断为导管内管状乳头状肿瘤(ITPN)。一名76岁男性患者出现体重减轻和主胰管扩张。影像学检查显示胰头主胰管内有一个30毫米的低血运肿瘤。内镜检查及活检显示高级别非典型上皮细胞,免疫染色模式提示为ITPN。在机器人辅助胰十二指肠切除术后,术后病理显示出相互矛盾的特征:ITPN典型的心形/筛状浸润以及PDAC特征性的非小叶性替代伴散在浸润。全面基因组分析检测发现KRAS和TP53突变,最终诊断为PDAC(fT3N1aM0,IIB期)。患者接受了辅助性S-1化疗,术后15个月无复发。该病例突出了区分胰腺导管内肿瘤的诊断挑战,并证明了将基因检测与传统诊断方法相结合对于准确诊断和合理选择治疗方法的实用性。